Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NYSE MKT LLC
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Oragenics Inc

+ Add to Watchlist

OGEN:US

1.0499 USD 0.0501 4.55%

As of 20:04:03 ET on 03/27/2015.

Snapshot for Oragenics Inc (OGEN)

Open: 1.1000 Day's Range: 1.0001 - 1.1240 Volume: 20,261
Previous Close: 1.1000 52wk Range: 0.7000 - 3.1100 1-Yr Rtn: -64.89%

Stock Chart for OGEN

No chart data available.
  • OGEN:US 1.0499
  • 1D
  • 1M
  • 1Y
1.1000
Interactive OGEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for OGEN

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.1639
Est. EPS (USD) (12/2015) -
Est. PEG Ratio -
Market Cap (M USD) 37.98
Shares Outstanding (M) 36.18
30 Day Average Volume 83,117
Price/Book (mrq) 3.6749
Price/Sale (ttm) 40.3740
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/08/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for OGEN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for OGEN

Oragenics, Inc. is a biotechnology research and development company seeking to commercialize technologies based on different strains of bacterias. The Company's technologies include a replacement therapy for tooth cavity protection and a new broad-spectrum antibiotic.

Michael O Sullivan "Mike"CFO/Treasurer/SecretaryMartin HandfieldSenior VP:Discovery Research
More Company Profile & Key Executives for OGEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil